Anna Quinton
BioPharmaceuticals R&D
Cambridge, ENG, United Kingdom
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Mapping EQ-5D-5L Score From SGRQ in Patients with Asthma and/or COPD in NOVELTY.
Journal: Pragmatic and observational research
Published: December 11, 2024
Response to Biologics Along a Gradient of T2 Involvement in Patients With Severe Asthma: A Data-Driven Biomarker Clustering Approach.
Journal: The journal of allergy and clinical immunology. In practice
Published: October 31, 2024
Real-World Biologic Use Patterns in Severe Asthma, 2015-2021: The CLEAR Study.
Journal: Pragmatic and observational research
Published: September 19, 2024
Disease Burden and Access to Biologic Therapy in Patients with Severe Asthma, 2017-2022: An Analysis of the International Severe Asthma Registry.
Journal: Journal of asthma and allergy
Published: March 09, 2024
Cost-effectiveness of tezepelumab in Canada for severe asthma.
Journal: Journal of medical economics
Published: July 07, 2023
Symptom Burden, Health Status, and Productivity in Patients with Uncontrolled and Controlled Severe Asthma in NOVELTY.
Journal: Journal of asthma and allergy
Published: December 14, 2022
Burden of Uncontrolled Severe Asthma With and Without Elevated Type-2 Inflammatory Biomarkers.
Journal: The journal of allergy and clinical immunology. In practice
Published: December 13, 2022
Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison.
Journal: Journal of medical economics
Published: May 16, 2022
Cluster Analysis of Inflammatory Biomarker Expression in the International Severe Asthma Registry.
Journal: The journal of allergy and clinical immunology. In practice
Published: February 16, 2021
Showing 1-9 of 9
Last Updated: 09/26/2026